UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease

Hakobyan, S; Harding, K; Aiyaz, M; Hye, A; Dobson, R; Baird, A; Liu, B; ... Morgan, BP; + view all (2016) Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. Journal of Alzheimer's Disease , 54 (2) pp. 707-716. 10.3233/JAD-160420. Green open access

[thumbnail of Dobson_jad_prepress_2Fjad_1_1_jad160420_2Fjad_1_jad160420_extracted.pdf]
Preview
Text
Dobson_jad_prepress_2Fjad_1_1_jad160420_2Fjad_1_jad160420_extracted.pdf - Accepted Version

Download (134kB) | Preview

Abstract

There is a critical unmet need for reliable markers of disease and disease course in mild cognitive impairment (MCI) and early Alzheimer's disease (AD). The growing appreciation of the importance of inflammation in early AD has focused attention on inflammatory biomarkers in cerebrospinal fluid or plasma; however, non-specific inflammation markers have disappointed to date. We have adopted a targeted approach, centered on an inflammatory pathway already implicated in the disease. Complement, a core system in innate immune defense and potent driver of inflammation, has been implicated in pathogenesis of AD based on a confluence of genetic, histochemical, and model data. Numerous studies have suggested that measurement of individual complement proteins or activation products in cerebrospinal fluid or plasma is useful in diagnosis, prediction, or stratification, but few have been replicated. Here we apply a novel multiplex assay to measure five complement proteins and four activation products in plasma from donors with MCI, AD, and controls. Only one complement analyte, clusterin, differed significantly between control and AD plasma (controls, 295 mg/l; AD, 388 mg/l: p < 10- 5). A model combining clusterin with relevant co-variables was highly predictive of disease. Three analytes (clusterin, factor I, terminal complement complex) were significantly different between MCI individuals who had converted to dementia one year later compared to non-converters; a model combining these three analytes with informative co-variables was highly predictive of conversion. The data confirm the relevance of complement biomarkers in MCI and AD and build the case for using multi-parameter models for disease prediction and stratification.

Type: Article
Title: Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease
Location: Netherlands
Open access status: An open access version is available from UCL Discovery
DOI: 10.3233/JAD-160420
Publisher version: http://dx.doi.org/10.3233/JAD-160420
Language: English
Additional information: The final publication is available at IOS Press through http://dx.doi.org/10.3233/JAD-160420.
Keywords: Alzheimer’s disease, biomarker, complement, inflammation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics > Clinical Epidemiology
URI: https://discovery.ucl.ac.uk/id/eprint/1521588
Downloads since deposit
151Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item